These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25336162)

  • 21. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.
    Fransen S; Gupta S; Danovich R; Hazuda D; Miller M; Witmer M; Petropoulos CJ; Huang W
    J Virol; 2009 Nov; 83(22):11440-6. PubMed ID: 19759152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.
    Fun A; Leitner T; Vandekerckhove L; Däumer M; Thielen A; Buchholz B; Hoepelman AIM; Gisolf EH; Schipper PJ; Wensing AMJ; Nijhuis M
    Retrovirology; 2018 Jan; 15(1):1. PubMed ID: 29304821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.
    Métifiot M; Maddali K; Naumova A; Zhang X; Marchand C; Pommier Y
    Biochemistry; 2010 May; 49(17):3715-22. PubMed ID: 20334344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation.
    Delelis O; Malet I; Na L; Tchertanov L; Calvez V; Marcelin AG; Subra F; Deprez E; Mouscadet JF
    Nucleic Acids Res; 2009 Mar; 37(4):1193-201. PubMed ID: 19129221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.
    Charpentier C; Karmochkine M; Laureillard D; Tisserand P; Bélec L; Weiss L; Si-Mohamed A; Piketty C
    HIV Med; 2008 Oct; 9(9):765-70. PubMed ID: 18651855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.
    Parczewski M; Bander D; Urbańska A; Boroń-Kaczmarska A
    BMC Infect Dis; 2012 Dec; 12():368. PubMed ID: 23259737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes.
    Quercia R; Dam E; Perez-Bercoff D; Clavel F
    J Virol; 2009 Oct; 83(19):10245-9. PubMed ID: 19605484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy.
    Ferns RB; Kirk S; Bennett J; Cook PM; Williams I; Edwards S; Pillay D
    AIDS; 2009 Oct; 23(16):2159-64. PubMed ID: 19571721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.
    Smith RA; Raugi DN; Kiviat NB; Hawes SE; Mullins JI; Sow PS; Gottlieb GS;
    AIDS; 2011 Nov; 25(18):2235-41. PubMed ID: 21971360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of raltegravir resistance during therapy.
    Sichtig N; Sierra S; Kaiser R; Däumer M; Reuter S; Schülter E; Altmann A; Fätkenheuer G; Dittmer U; Pfister H; Esser S
    J Antimicrob Chemother; 2009 Jul; 64(1):25-32. PubMed ID: 19447792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
    Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M
    J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.
    Charpentier C; Larrouy L; Matheron S; Damond F; Delelis O; Mouscadet JF; Campa P; Chêne G; Brun-Vézinet F; Descamps D;
    Antivir Ther; 2011; 16(6):937-40. PubMed ID: 21900727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences.
    Grobler JA; Hazuda DJ
    Curr Opin Virol; 2014 Oct; 8():98-103. PubMed ID: 25128610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor].
    Delaugerre C
    Med Mal Infect; 2010 Sep; 40 Suppl 1():S1-10. PubMed ID: 20800182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages.
    Marsden MD; Avancena P; Kitchen CM; Hubbard T; Zack JA
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3696-702. PubMed ID: 21628534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
    Malet I; Wirden M; Fourati S; Armenia D; Masquelier B; Fabeni L; Sayon S; Katlama C; Perno CF; Calvez V; Marcelin AG; Ceccherini-Silberstein F
    J Antimicrob Chemother; 2011 Jul; 66(7):1481-3. PubMed ID: 21474479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.
    Armenia D; Fabeni L; Alteri C; Di Pinto D; Di Carlo D; Bertoli A; Gori C; Carta S; Fedele V; Forbici F; D'Arrigo R; Svicher V; Berno G; Pizzi D; Nicastri E; Sarmati L; Pinnetti C; Ammassari A; D'Offizi G; Latini A; Andreoni M; Antinori A; Ceccherini-Silberstein F; Perno CF; Santoro MM
    J Antimicrob Chemother; 2015; 70(6):1865-73. PubMed ID: 25712318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 subtype F integrase polymorphisms external to the catalytic core domain contribute to severe loss of replication capacity in context of the integrase inhibitor resistance mutation Q148H.
    Aulicino PC; Momin Z; Rozenszajn M; Monzon A; Arazi-Caillaud S; Bologna R; Mangano A; Kimata JT
    J Antimicrob Chemother; 2022 Sep; 77(10):2793-2802. PubMed ID: 35897124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations.
    Garrido C; de Mendoza C; Alvarez E; García F; Morello J; Garcia S; Ribera E; Rodríguez-Novoa S; Gutierrez F; Soriano V;
    AIDS Res Hum Retroviruses; 2012 Feb; 28(2):156-64. PubMed ID: 21457126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations.
    Mouscadet JF; Arora R; André J; Lambry JC; Delelis O; Malet I; Marcelin AG; Calvez V; Tchertanov L
    J Mol Recognit; 2009; 22(6):480-94. PubMed ID: 19623602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.